Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA.
Cancer Res. 2013 Mar 15;73(6):1689-98. doi: 10.1158/0008-5472.CAN-12-3391. Epub 2013 Jan 17.
While there is an increasing role of ultrasound for breast cancer screening in patients with dense breast, conventional anatomical ultrasound lacks sensitivity and specificity for early breast cancer detection. In this study, we assessed the potential of ultrasound molecular imaging using clinically translatable vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted microbubbles (MB(VEGFR2)) to improve the diagnostic accuracy of ultrasound in earlier detection of breast cancer and ductal carcinoma in situ (DCIS) in a transgenic mouse model [FVB/N-Tg(MMTV-PyMT)634Mul]. In vivo binding specificity studies (n = 26 tumors) showed that ultrasound imaging signal was significantly higher (P < 0.001) using MB(VEGFR2) than nontargeted microbubbles and imaging signal significantly decreased (P < 0.001) by blocking antibodies. Ultrasound molecular imaging signal significantly increased (P < 0.001) when breast tissue (n = 315 glands) progressed from normal [1.65 ± 0.17 arbitrary units (a.u.)] to hyperplasia (4.21 ± 1.16), DCIS (15.95 ± 1.31), and invasive cancer (78.1 ± 6.31) and highly correlated with ex vivo VEGFR2 expression [R(2) = 0.84; 95% confidence interval (CI), 0.72-0.91; P < 0.001]. At an imaging signal threshold of 4.6 a.u., ultrasound molecular imaging differentiated benign from malignant entities with a sensitivity of 84% (95% CI, 78-88) and specificity of 89% (95% CI, 81-94). In a prospective screening trail (n = 63 glands), diagnostic performance of detecting DCIS and breast cancer was assessed and two independent readers correctly diagnosed malignant disease in more than 95% of cases and highly agreed between each other [intraclass correlation coefficient (ICC) = 0.98; 95% CI, 97-99]. These results suggest that VEGFR2-targeted ultrasound molecular imaging allows highly accurate detection of DCIS and breast cancer in transgenic mice and may be a promising approach for early breast cancer detection in women.
虽然超声在致密型乳腺的乳腺癌筛查中发挥着越来越大的作用,但传统的解剖超声在早期乳腺癌检测方面的灵敏度和特异性较低。在这项研究中,我们评估了使用临床可转化的血管内皮生长因子受体 2(VEGFR2)靶向微泡(MB(VEGFR2))进行超声分子成像的潜力,以提高超声在早期检测乳腺癌和乳腺导管原位癌(DCIS)中的诊断准确性,该研究在转基因小鼠模型[FVB/N-Tg(MMTV-PyMT)634Mul]中进行。体内结合特异性研究(n=26 个肿瘤)表明,与非靶向微泡相比,超声成像信号显著升高(P<0.001),并且通过阻断抗体,成像信号显著降低(P<0.001)。当乳腺组织(n=315 个腺体)从正常[1.65±0.17 个任意单位(a.u.)]进展为增生(4.21±1.16)、DCIS(15.95±1.31)和浸润性癌(78.1±6.31)时,超声分子成像信号显著增加(P<0.001),并且与体外 VEGFR2 表达高度相关[R2=0.84;95%置信区间(CI),0.72-0.91;P<0.001]。在成像信号阈值为 4.6 a.u.时,超声分子成像以 84%(95%CI,78-88)的灵敏度和 89%(95%CI,81-94)的特异性区分良性和恶性实体。在一项前瞻性筛查试验(n=63 个腺体)中,评估了检测 DCIS 和乳腺癌的诊断性能,两位独立的读者在超过 95%的病例中正确诊断出恶性疾病,并且彼此之间高度一致[组内相关系数(ICC)=0.98;95%CI,97-99]。这些结果表明,VEGFR2 靶向超声分子成像可高度准确地检测转基因小鼠中的 DCIS 和乳腺癌,并且可能是女性早期乳腺癌检测的一种有前途的方法。